Abstract
Serum carcinoembryonic antigens (CEA), CA 15-3, and tissue polypeptide antigens (TPA) have been used in monitoring the clinical course of patients with breast cancer. However, recent reports have suggested that the serial levels of these markers during therapy do not always correlate with the response to therapy. To clarify the usefulness of the serial combination assay of these markers in monitoring the clinical course of patients during therapy, we investigated the relationship between the initial changes and the kinetic patterns of the markers after therapy and the objective responses. When an increase or decrease of over 20% in these markers is taken to be significant, then the initial changes in all three markers significantly correlated with the therapeutic responses (P<0.01). Five distinct kinetic patterns in the marker levels were observed. A paradoxical kinetic pattern of CEA and CA 15-3 levels — that is, an “initial surge and subsequent drop” — was seen in one-third of the responders. The TPA levels tended to exhibit a “steady decline” pattern in those responders. The sensitivity and specificity of the kinetic patterns to predict the clinical courses were significantly higher than those obtained from the analysis of initial changes. These findings thus suggest that adequate knowledge of the unique kinetics of each marker may help to make a more accurate prediction of the therapeutic responses.
References
Chu TM, Nemoto T (1973) Evaluation of carcinoembryonic antigen in human mammary carcinoma. J Natl Cancer Inst 51:1119–1122
Steward AM, Nixon D, Zamcheck N, Aisenberg A (1974) Carcinoembryonic antigen in breast cancer patients: serum levels and disease progress. Cancer 33:1246–1252
Tormey DC, Waalkes TP, Snyder JJ, Simon RM (1977) Biological markers in breast carcinoma. III. Clinical correlations with carcinoembryonic antigen. Cancer 39:2397–2404
Woo KB, Waalkes TP, Ahmann DL, Tormey DC, Gehrke CW, Oliverio VT (1978) A quantitative approach to determining disease response during therapy using multiple biologic markers. Cancer 41:1685–1703
Falkson HC, Van der Watt JJ, Portugal MA, Pitout MJ, Falkson G (1978) Carcinoembryonic antigen in patients with breast cancer. An adjunctive tool to monitor response and therapy. Cancer 42:1308–1313
Haagensen DE, Kister SJ, Vandevoorde JP, Gates JB, Smart EK, Hansen HJ, Wells SA (1978) Evaluation of carcinoembryonic antigen as a plasma monitor for human breast carcinoma. Cancer 42:1512–1519
Myers RE, Sutherland DJ, Meakin JW, Kellen JA, Malkin DG, Markin A (1978) Carcinoembryonic antigen in breast cancer. Cancer 42:1520–1526
Haagensen DE Jr, Kister SJ, Panick J, Giannola J, Hansen HJ, Wells SA (1978) Comparative evaluation of carcinoembryonic antigen and gross cystic disease fluid protein as plasma markers for human breast carcinoma. Cancer 42:1646–1652
Lokich JJ, Zamcheck N, Lowenstein M (1978) Sequential carcinoembryonic antigen levels in the therapy of metastatic breast cancer. Ann Int Med 89:902–906
Haagensen DE Jr, Barry WF, Mccook TA, Giannola J, Ammirata S, Wells SA (1980) The value of serial plasma levels of carcinoembryonic antigen and gross cystic disease fluid protein in patients with breast carcinoma and osseous metastases. Ann Surg 5:599–603
Staab HJ, Ahlemann LM, Koch HL (1980) Serial CEA determination in the management of patients with breast cancer. Oncodevelop Biol Med 1:151–160
Silva JS, Leight GS, Haagensen DE Jr, Tallos PB, Cox EB, Dilley WG, Wells SA (1982) Quantitation of response to therapy in patients with metastatic breast carcinoma by serial analysis of plasma gross cystic disease fluid protein and carcinoembryonic antigen. Cancer 49:1236–1242
Mughal AW, Hortobagyi GN, Fritsche HA, Buzdar AU, Yap HY, Blumenschein GR (1983) Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA 249:1881–1886
Waalkes TP, Enterline JP, Shaper JH, Abeloff MD, Ettinger DS (1984) Biological markers for breast carcinoma. Cancer 53:644–651
Beard DB, Haskell CM (1986) Carcinoembryonic antigen in breast cancer. Am J Med 80:241–245
Hayes DF, Zurawski VR, Kufe DW (1986) Comparison of circulating CA 15-3 and carcinoembryonic antigen in patients with breast cancer. J Clin Oncol 4:1542–1550
Pons-Anicet DMF, Krebs BP, Mira R, Namer M (1987) Value of CA 15:3 in the follow-up of breast cancer patients. Br J Cancer 55:567–569
Tondini C, Hayes DF, Gelman R, Henderson TC, Kufe DW (1988) Comparison of CA 15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 48:4107–4112
Colomer R, Ruibal A, Salvador L (1989) Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64:1674–1681
Kiang DT, Greenberg LJ, Kennedy BJ (1990) Tumor marker kinetics in the monitoring of breast cancer. Cancer 65:193–199
Gion M, Mione R, Gatti C, Dittadi R, Leon A, Nascimben O, Pizzorno B, Bruscagnin G (1990) Is tissue polypeptide antigen still a useful tumor marker in breast carcinoma? Comparison with CA 15-3 and MCA. Tumori 76:360–364
Jotti GS, Bombardieri E (1990) Circulating tumor markers in breast cancer. Anticancer Res 10:253–258
Frabcini G, Montagnani M, Petrioli R, Paffetti P, Marsili S, Leone V (1990) Comparison between CEA, TPA, CA 15/3 and hydroxyproline, alkaline phosphatase, whole body retention of 99mTc MDP in the follow-up of bone metastases in breast cancer. Int J Biol Markers 5:65–72
Barak M, Steiner M, Finkel B, Abrahamson J, Antal S, Gruener N (1990) CA 15-3, TPA and MCA as markers for breast cancer. Eur J Cancer 26:577–580
Nicolini A, Colombini C, Luciani L, Carpi A, Giuliani L (1991) Evaluation of serum CA 15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer 64:154–158
O'Brien DP, Horgan PG, Gough DB, Skehill R, Grimes H, Given HF (1992) CA 15-3: a reliable indicator of metastatic bone disease in breast cancer patients. Ann R Coll Surg Engl 74:9–11
Geraghty JG, Coveney EC, Sherry F, O'Higgins NJ, Duffy MJ (1992) CA 15-3 in patients with locoregional and metastatic breast carcinoma. Cancer 70:2831–2834
Loprinzi CL, Tormey DC, Rasmussen P, Falkson G, Davis TE, Falkson HC, Chang AYC (1986) Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. J Clin Oncol 4:46–56
Hayward JL, Rubens RD, Carbone P, Heuson JC, Kumaoka S, Segaloff A (1977) Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 39:1289–1294
Kurebayashi J, Kurosumi M, Sonoo H (1995) A new human breast cancer cell line, KPL-1, secretes tumour-associated antigens and grows rapidly in female athymic nude mice. Br J Cancer 71:845–853
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sonoo, H., Kurebayashi, J. Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer. Surg Today 26, 250–257 (1996). https://doi.org/10.1007/BF00311583
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00311583